The purpose of this study is to show that Dysport is as safe as Botox when used to treat adults with upper limb spasticity by looking at side effects that occur during the first 12 weeks after the injection. Both medicines will be injected into specific muscles in the arm, including muscles that control the wrist, fingers, and elbow. The study will use a crossover design, which means that participants will receive both treatments at different times during the study, allowing doctors to compare how well each medicine works for the same person. The total amount of medicine given will be 900 units for Dysport or 360 units for Botox, depending on which treatment is being given at that time.

During the study, doctors will check for any unwanted effects or side effects that may occur after the injections. They will also measure how well the muscles respond to treatment by checking muscle stiffness, how well the arm functions in daily activities like dressing and hygiene, and whether there is any pain. These measurements will be taken at several visits over a period of up to 24 weeks. The study will also look at how long the treatment effects last before another injection is needed and will ask participants about their overall quality of life and how they feel about their treatment response.

The purpose of this research is to determine if Pregabalin works better than Baclofen in treating patients who have sudden, dynamic muscle spasms following spinal cord injury. The medications will be given as white capsules taken by mouth. Patients will receive either Pregabalin (up to 600 mg per day) or Baclofen (up to 100 mg per day) for a period of 30 days.

During the study, healthcare providers will monitor how well the medications control muscle spasms and stiffness. They will also assess how the treatments affect the patients’ ability to perform daily activities and their overall quality of life. To ensure reliable results, neither the patients nor their healthcare providers will know which medication is being given.

The study is conducted in several stages. Initially, different doses of IPN10200 are tested to find the safest and most effective dose. Participants receive a single injection of the medication, and their response is monitored. In later stages, the selected doses are further tested to confirm their safety and effectiveness. The study also includes an open-label extension period, where participants who have completed the earlier stages can continue to receive IPN10200 to assess its long-term safety and benefits.

Throughout the study, participants are closely monitored for any side effects or changes in their condition. The study aims to find the best dose of IPN10200 that provides the desired relief from spasticity while ensuring safety. This research could lead to improved treatment options for individuals experiencing upper limb spasticity after a stroke or traumatic brain injury.

The purpose of the study is to explore how this treatment affects the muscles, tendons, and nerves in patients with spastic equinovarus after a stroke. The study will use advanced techniques like Three Dimensional freehand Ultrasound (3DfUS) and Instrumented Spasticity Assessment (ISA) to observe these changes. These methods help in understanding how the treatment works and in improving future treatment plans for patients with this condition.

Participants in the study will receive the treatment and be monitored over time to see how their condition changes. The study aims to gather information that could help optimize treatment strategies and improve long-term outcomes for people with spastic equinovarus following a stroke. The study will not involve any other medications or treatments, and some participants may receive a placebo for comparison purposes.

The purpose of the study is to determine the most effective dose of Riluzole for reducing spasticity and to compare its effectiveness against a placebo. The study will be conducted in two steps. In the first step, researchers will identify the minimal effective dose of Riluzole that helps improve spasticity. In the second step, they will assess how well this dose works compared to the placebo. Participants will take the medication orally, and the study will monitor changes in their condition over time.

Throughout the study, participants will be evaluated for any side effects and changes in their spasticity levels. The study will also look at other factors such as pain levels, muscle function, and overall quality of life. The trial is designed to be adaptive, meaning it can adjust based on the results observed during the study. This approach helps ensure that the most effective treatment options are identified for individuals with chronic spinal cord injury and spasticity.

The purpose of this research is to evaluate how well IncobotulinumtoxinA works and how safe it is when the dose is customized for each person’s specific needs. The study focuses on people who have severe muscle stiffness affecting both their arms and legs. The treatment involves receiving injections of the medication, and patients will be monitored for changes in their muscle stiffness and pain levels.

During the study, participants will receive Xeomin (the brand name for IncobotulinumtoxinA) injections. The effects of the treatment will be checked several times over a period of 12 weeks after the injection. The study will look at improvements in muscle stiffness, pain levels, and ability to perform daily activities. The treatment dose will be adjusted based on each person’s specific muscle stiffness patterns.

Participants in the study will receive a single injection of NT 201 or a placebo. The study will compare the effects of NT 201 to the placebo over a period of several weeks. The main goal is to see if NT 201 can improve muscle stiffness in the legs of children and adolescents with cerebral palsy between the fourth and sixth week after the injection. The study will also include an open-label extension period, where all participants may receive NT 201, to further assess its long-term effects.

The study is designed to be prospective, meaning it looks forward in time, and randomized, which means participants are randomly assigned to receive either NT 201 or a placebo. It is also double-blind, so neither the participants nor the researchers know who is receiving the actual treatment or the placebo during the initial phase. This helps ensure that the results are unbiased. The study will take place in multiple centers, allowing for a diverse group of participants to be involved.

The main purpose of this research is to understand how these two treatments affect spasticity at the spinal cord level. The study will monitor changes in muscle stiffness, walking ability, and quality of life over several weeks. Participants will receive either Botox injections or dry needling treatment, and their progress will be tracked through various measurements and tests.

The study will last approximately 19 weeks, during which participants will undergo regular assessments of their muscle condition, walking ability, and overall function. The research team will use various tools to measure improvements, including walking tests and ultrasound imaging of the muscles. They will also evaluate which treatment provides better value for the cost.

The purpose of the study is to investigate how effective and safe IncobotulinumtoxinA is for treating spasticity in both the upper and lower limbs of children with cerebral palsy. The study will involve a dose titration approach, which means adjusting the dose of the medication to find the most effective amount for each child. The study will take place over three injection cycles, with observation periods lasting between 12 to 20 weeks after each injection. The total duration of the study for each participant can be up to 60 weeks.

During the study, children will receive injections of IncobotulinumtoxinA and will be monitored for changes in muscle stiffness and overall movement ability. The study will also track any side effects or adverse events to ensure the safety of the treatment. The goal is to determine if this treatment can help improve the quality of life for children with cerebral palsy by reducing muscle spasticity and improving their ability to move.